Lilly To Release Data Targeting Key Cancer Pathways At AACR 2014

Eli Lilly will present early-stage data from several targeted cancer therapies–including bemaciclib (LY2835219), its oral, cell-cycle inhibitor of CDK4/6–that make up its clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014. Lilly's oncology pipeline includes a range of large and small molecules being investigated to treat variety of cancers including lung, breast, colorectal, gastric, liver, and hematologic malignancies.

Data from bemaciclib as a potential treatment for metastatic breast cancer, has been accepted as a presentation at AACR's Clinical Trials Symposium and will be featured in an AACR-sponsored press conference.

Lilly's B-Raf inhibitor LY3009120 will be displayed at AACR's New Drugs on the Horizon special session where there will be discussions regarding new anti-cancer compounds that target key pathways. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.

Source: Eli Lilly